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Two optimized pranoprofen-loaded poly-L-lactic-co glycolic acid (PLGA) nanoparticles (PF-F1NPs; PF-
F2NPs) have been developed and further dispersed into hydrogels for the production of semi-solid formu-
lations intended for ocular administration. The optimized PF-NP suspensions were dispersed in freshly
prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone
(HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical proﬁle
of the selected non-steroidal anti-inﬂammatory drug (NSAID), by prolonging the contact of the pranopro-
fen with the eye, increasing the drug retention in the organ and enhancing its anti-inﬂammatory and
analgesic efﬁciency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations
with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for
ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sus-
tained release behavior. The results obtained from ex vivo corneal permeation and in vivo anti-inﬂamma-
tory efﬁcacy studies suggest that the ocular application of the hydrogels containing azone was more
effective over the azone-free formulations in the treatment of edema on the ocular surface. No signs of
ocular irritancy have been detected for the produced hydrogels.
 2015 Elsevier B.V. All rights reserved.55
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741. Introduction
Pranoprofen is a non-steroidal anti-inﬂammatory drug (NSAID)
which can be used as a safe and effective alternative anti-inﬂam-
matory treatment following strabismus and cataract surgery [1–
3]. This drug has the beneﬁcial effect of reducing the ocular signs
and symptoms of dry eye and decreasing the inﬂammatory mark-
ers of conjunctival epithelial cells [4]. Its efﬁcacy is equivalent to
moderate-potency corticosteroids, but it has improved safety pro-
ﬁle. It should be considered for the treatment of chronic conjunc-
tivitis of presumed nonbacterial origin [5]. Although this drug
has shown high anti-inﬂammatory and analgesic efﬁciency, the
pharmaceutical use of pranoprofen is limited due to its inadequate
biopharmaceutical proﬁle. Pranoprofen has a short plasmatic half-
life, low water solubility and is unstable in aqueous solution, par-
ticularly when exposed to light [6,7]. Pranoprofen is commercially
available as eye-drops (0.1% m/V). However, this conventional dos-ocular
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
Table 1
Composition of the optimized pranoprofen-loaded nanoparticles.
PF-NPs cPF (mg/mL) cPVA (mg/mL) cPLGA (mg/mL) pH
PF-F1NPs 1.5 10.0 9.5 5.5
PF-F2NPs 1.0 5.0 9.0 4.5
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16 February 2015age form cannot be considered optimal in the treatment of ocular
diseases due to the fact that upon instillation most of the drugs
are removed from the surface of the eye, by various mechanisms
(tear dilution and tear turn over). Moreover, the relatively imper-
meable corneal barrier restricts the entry of foreign substances.
As a result, less than 5% of the administered drug penetrates the
cornea and reaches intraocular tissue [8]. Polymeric NPs are one
of the colloidal systems that have been most widely studied over
the past few decades with the objective of improving drug target-
ing of tissues and organs and increase drug bioavailability across
biological membranes. Biodegradable polymers, such as poly (lac-
tic-co-glycolic) acid (PLGA), have been widely used in drug delivery
research, in part due to their approval by the FDA for use in
humans and they can effectively deliver the drug to a target site
with a controllable degradation [9]. PLGA can be used such as
matrix to load different drugs for topical administration [10–12].
Different drug delivery systems have been studied in order to
improve drug targeting of tissues, increase drug bioavailability
across biological membranes or reducing its toxicity. For topical
application of nanoparticle suspensions, several of these systems
have been dispersed in semi-solid vehicles such as hydrogels or
cream [13,14]. Among the gelling agents, carbomer has been
extensively used for design topical formulations [15–17]. In addi-
tion, to improve the permeability of drugs through the ocular bar-
riers, different enhancers have also been tested. Azone is one of the
most widely studied penetration enhancers which can be used as a
safe and effective penetration enhancer for human use in the range
of 1–10% [18]. In previous studies, we have formulated pranopro-
fen in PLGA nanoparticles (PF-NPs) using the solvent displacement
technique [19]. A 24 central composite factorial design has been
applied to study the main effects and interactions of four factors
on average particle size (Z-Ave), polydispersity index (PI), zeta
potential (ZP) and entrapment efﬁciency (EE). The factors studied
were PF concentration (cPF), PVA concentration (cPVA), PLGA
concentration (cPLGA) and aqueous phase pH. From a total of 26
formulations obtained by factorial design, two optimum formula-
tions (PF-F1NPs and PF-F2NPs) were selected for further investiga-
tion here [20]. The aim of this study was designed semi-solid
formulations containing pranoprofen loaded-PLGA nanoparticles
for ocular administration. Carbomer 934 was selected to disperse
the optimized PF-NP suspension because of the bioadhesive prop-
erties, low or no toxicity, rheological characteristics and biocom-
patibility of the hydrophilic polymer. Polyacrylic acid hydrogels
such as Carbomer 934, polycarbophil and carboxymethylcellulose
have been reported as the most appropriate bioadhesive polymers
for ocular drug delivery [21]. Additionality, the high viscosity of the
carbomer hydrogels ensures the prolonged retention improving
the ocular bioavailability of some drugs [22]. The optimized PF-
F1NP and PF-F2NP suspensions were dispersed into blank hydro-
gels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing
1% azone (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order
to improve the biopharmaceutical proﬁle of pranoprofen in the
eye, by increasing is ocular retention and improving the anti-
inﬂammatory and analgesic efﬁciency. The ultimate aim of the
developed formulations is to improving the patient’s compliance
to the pharmacological treatment by reducing the application fre-
quency. In this study, azone was selected as permeation enhancer
with the purpose to improve the permeability of pranoprofen from
PF-NPs based HG through the ocular barriers. Azone is one of the
most widely studied penetration enhancers for hydrophilic and
lipophilic drugs. As a penetration enhancer, azone is more effective
at low percentages (1–3%), and it has also been reported to be of
low irritancy and very low toxicity [23]. The mechanism of azone
may be related to some changes in the epithelial cell junctions of
the cornea, which are nevertheless reversible in cornea structure
[24,25].Please cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpThe physicochemical properties and the rheological behavior of
HG_PF-NP formulations have been characterized. The physical sta-
bility of the nanoparticles incorporated into hydrogels has also
been evaluated. In vitro release proﬁle and ex vivo corneal perme-
ation of pranoprofen from the semi-solid formulations, as well as
their in vitro e in vivo ocular tolerance and the anti-inﬂammatory
efﬁcacy have also been assayed.
2. Materials and methods
2.1. Materials
Pranoprofen and Oftalar

were kindly supplied by Alcon Cusi
(Barcelona, Spain); PLGA Resomer

753S was obtained from Boeh-
ringer Ingelheim (Ingelheim, Germany). Polyvinyl alcohol (PVA)
with 90% hydrolyzation and Arachidonic acid sodium (SA) were
obtained from Sigma Aldrich (St. Louis, USA). Gel-forming polymer
(Carbomer 934) was obtained from Fagron Ibérica. The puriﬁed
water used in all the experiments was obtained from a MilliQ Sys-
tem. All the other chemicals and reagents used in the study were of
analytical grade.
2.2. Methods
2.2.1. Preparation of pranoprofen-loaded nanoparticles
The nanoparticles have been produced by the solvent displace-
ment technique, described by Fessi et al. [19]. PLGA (90 mg or
95 mg) and pranoprofen (10 mg or 15 mg) were dissolved in
5 mL of acetone. This organic phase was poured, under moderate
stirring into 10 mL of an aqueous solution of PVA (5 mg/mL or
10 mg/mL) adjusted to the desired pH value (4.5 or 5.5). The ace-
tone was then evaporated and the dispersed nanoparticles were
concentrated to 10 mL under reduced pressure (Büchi B-480 Fla-
wil, Switzerland). Table 1 shows the composition of the optimized
pranoprofen-loaded nanoparticles.
2.2.2. Mean particle size and zeta potential
The mean particle size (Z-Ave) and the zeta potential (ZP) of the
nanoparticles were determined by photon correlation spectros-
copy (PCS) with a Zetasizer Nano ZS (Malvern Instruments, Mal-
vern, UK) at 25 C using disposable quartz cells and disposable
folded capillary zeta cells (Malvern Instruments, Malvern, UK),
respectively. For all measurements, the samples were diluted with
MilliQ water (1:20). The reported values are the mean ± SD of at
least three different batches of each formulation.
2.2.3. Encapsulation efﬁciency
The encapsulation efﬁciency (EE) of pranoprofen in the
nanoparticles was determined indirectly by measuring the
concentration of the free drug in the dispersion medium. The
non-encapsulated pranoprofen was separated using a ﬁltration/
centrifugation technique with Ultracel-100K (Amicon

Ultra,
Millipore Corporation, Billerica, MA) centrifugal ﬁlter devices at
3000 rpm for 30 min at 4 C (Heraeus, Multifuge 3 L-R, centrifuge.
Osterode, Germany). Each sample was diluted with MilliQ water
(1:20) prior to ﬁltration/centrifugation. The EE was calculated
using the following equation:f pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
b.2015.01.026
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16 February 2015EEð%Þ ¼ Total Amount of pranoprofen Free drug
Total Amount of pranoprofen
 100 ð1Þ
The assay was carried out by high performance liquid chroma-
tography (HPLC) using a method previously validated in our labo-
ratory. The detection and quantiﬁcation limits (LOD and LOQ)
found for the validated method were 1.05 ± 0.70 lg/mL and
3.17 ± 2.12 lg/mL, respectively. The HPLC system consisted of a
Waters 1525 pump (Waters, Milford, USA) with a UV–Vis 2487
detector (Waters), a ﬂow rate of 1 mL/min and wavelength of
245 nm were used with a (Kromasil

, 100-5C18, 4.6  100 mm)
column. The mobile phase consisted of methanol: glacial acetic
acid 5% (45: 55, v: v).
2.3. Preparation of pranoprofen-loaded nanoparticles dispersed in
hydrogels
The blank hydrogels were prepared with carbomer (1% w/v),
dispersed in puriﬁed water and allowed to hydrate for 24 h. Subse-
quently, glycerol (3% w/w) and azone (0% or 1% w/w) were incor-
porated into the hydrogel by stirring for 5 min at 1000 rpm in a
high speed stirred (Cito Unguator Konietzko, Bamberg, Germany)
and then the pH was adjusted at 6.5 with 0.1 N NaOH. The HG
was left to equilibrate for 24 h at room temperature before used.
The optimized aqueous PF-NP suspensions were incorporated into
HG with 0% or 1% azone using a high speed stirred by 3 min at
1000 rpm, in a concentration of 50% (w/w) of the nanoparticle dis-
persion into the hydrogel.
2.4. Physicochemical characterization of the hydrogels
The morphological examination of the NPs incorporated into
HG was performed by Transmission Electron Microscopy (TEM).
The sample was dispersed in MilliQ water using an Elma Trans-
sonic Digital S T490 DH ultrasonic bath (Elma, Singen, Germany).
A drop of this dispersion (10 lL) was placed on copper electron
microscopy grids and stained with a 2% (w/v) uranyl acetate solu-
tion. After 1 min, the sample was washed with ultra-puriﬁed water
and the excess ﬂuid removed with a piece of ﬁlter paper. The dried
sample was then examined.
The physical stability of the HG_PF-NP formulations was
assessed after 1 day of the production and 90 days of storage at
25 C. The Z-Ave and ZP of the particles were determined by pho-
ton PCS as described above. The diameter of the nanoparticles dis-
persed into the hydrogels also was measured by laser diffraction
(LD) data, obtained with a Mastersizer Hydro 2000MU (Malvern
Instruments Ltd., Malvern, UK), using the volume distribution as
diameter values of LD 10%, LD 50% and LD 90%. The diameter values
indicate the percentage of nanoparticles showing a diameter equal
or lower than the given value. For all measurements, the samples
were dispersed in MilliQ water using an Elma Transsonic Digital
S T490 DH ultrasonic bath (Elma, Singen, Germany).
2.5. Rheological measurements of the hydrogels
The hydrogel samples were placed in glass vials with rubber top
and aluminum capsule and storage at 25 C ± 2 C. The rheological
characterization of each formulation was performed using a Haake
Rheostress1 rheometer (Thermo Fisher Scientiﬁc, Karlsruhe,
Germany) connected to a temperature control Thermo Haake
Phoenix II + Haake C25P and equipped with parallel plate geome-
try (Haake PP60 Ti, 60 mm diameter, 0.5 mm gap between plates)
or cone plate set-up with a ﬁxed lower plate and a mobile upper
cone (Haake C35/2 Ti, 35 mm diameter, 0.106 mm gap between
cone-plate). The viscosity curves and ﬂow curves were recorded
under rotational runs at 25 C for 3 min during the ramp-up periodPlease cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpfrom 0 to 100 s1, 1 min at 100 s1 (constant share rate period) and
ﬁnally 3 min during the ramp-down period from 100 to 0 s1. Vis-
cosity values at 100 s1 were determined after 8 days of the pro-
duction and 90 days of storage at 25 ± 2 C, in three replicates.
Oscillatory stress sweep tests were performed at a constant fre-
quency of 1 Hz in a stress range of 0.1 and 200 Pa. Oscillation fre-
quency tests were carried out from 0.01 to 10 Hz at a constant
shear stress within the linear viscoelastic region, in order to deter-
mine the related variation of storage modulus (G0) and loss modu-
lus (G00) at 25 C. The software Haake RheoWin

Job Manager V.3.3
and RheoWin

Data Manager V.3.3 (Thermo Electron Corporation,
Karlsruhe, Germany) were used to carry out the test and analysis
of the obtained data, respectively.
2.6. In vitro pranoprofen release from the hydrogels
In vitro release study of pranoprofen from the HG_PF-NP formu-
lations was performed in Franz diffusion cells [26]. These cells con-
sist of a donor and a receptor chamber between which a membrane
is positioned. A dialysis membrane (MWCO 12,000–14,000 Da.,
Dialysis Tubing Visking, Medicell International Ltd., London, UK)
was used. The membrane was hydrated for 24 h before being
mounted in the Franz diffusion cell. The experiment was per-
formed under ‘‘sink condition’’. The HG_PF-NP formulations were
compared with the commercial eye drops (Oftalar

, pranoprofen
1 mg/mL) and the free drug (1 mg/mL) dissolved in phosphate buf-
fer solution (PBS) at pH 7.4. A weight of 400 mg of the HG_PF-NP
formulations or a volume of 200 lL of the free drug solution and
commercial eye drops was placed in the donor compartment and
the receptor compartment was ﬁlled with PBS at pH 7.4 kept at
37 ± 0.5 C. A volume of 300 lL was withdrawn from the receptor
compartment at ﬁxed times and replaced by an equivalent volume
of fresh PBS at the same temperature. The concentration of prano-
profen released was measured as described previously for EE. Val-
ues are reported as the mean ± SD of three replicates.
The amount pranoprofen release was adjusted to the following
kinetic models [27]:
Zero order : %Rt=%R1 ¼ k t ð2Þ
First order : %Rt=%R1 ¼ 1 ekt ð3Þ
Higuchi : %Rt=%R1 ¼ k t1=2 ð4Þ
Hyperbola : %Rt=%R1 ¼ R1  t=ðkþ tÞ ð5Þ
Korsmeyer—Peppas : %Rt=%R1 ¼ k tn ð6Þ
where %Rt is the percentage of the drug released at time t, %R1 is the
total percentage of drug released, %Rt/%R1 is the fraction of
drug released at time t, k is the release rate constant and n is the dif-
fusion release exponent that can be used to characterize the differ-
ent release mechanisms; n 6 0.5 (Frickian diffusion), 0.5 < n < 1.0
(anomalous transport), and nP 1 (case II transport, i.e., zero-order
release). A nonlinear least-squares regression was performed using
the WinNonLin

software (WinNonLin

professional edition version
3.3 and Graphpad prism version 6 Demo) and the model parameters
were calculated. Akaike’s information criterion (AIC) was deter-
mined for each model as an indicator of the model’s suitability for
a given dataset [28].
2.7. Corneal permeation study
Ex vivo corneal permeation experiments were carried out with
New Zealand rabbits (male, weighing 2.5–3.0 kg), under veterinary
supervision and according to the Ethics Committee of Animals
Experimentation at the University of Barcelona. The rabbits were
anesthetized with intramuscular administration of ketamine HCl
(35 mg/kg) and xylazine (5 mg/kg). The animals were euthanizedf pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
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16 February 2015by an overdose of sodium pentobarbital (100 mg/kg) administered
through marginal ear vein under deep anesthesia. The corneas,
with 2 mm ring of sclera were excised and immediately trans-
ported to the laboratory in artiﬁcial tear solution. The assay was
done using Franz diffusion Cells. The cornea was ﬁxed between
the donor and receptor compartment of Franz cell. The corneal area
available for permeation was 0.64 cm2. The receptor compartment
was ﬁlled with freshly prepared Bicarbonate Ringer’s (BR) solution.
This compartment was kept at 37 ± 0.5 C and stirred continuously.
A weight of 1 g of the HG_PF-NP formulations or 1 mL of the com-
mercial eye drops and free drug solution was placed in the donor
compartment (covered with paraﬁlm

in order to avoid evapora-
tion). A volume of 300 lL was withdrawn from the receptor com-
partment at ﬁxed times and replaced by an equivalent volume of
fresh BR solution at the same temperature. The cumulative prano-
profen amount permeated through the cornea per unit area (lg/
cm2) was calculated, at each time point, from cPF in the receiving
medium and plotted as function time (min).
2.8. Amount of pranoprofen retained in the cornea
At the end of the study, the cornea was used to determine the
amount of drug retained. The cornea was carefully freed from the
sclera ring, cleaned using a 0.05% solution of sodium lauryl sulfate
and washed with distilled water, weighed and treated with meth-
anol: water (50:50, V/V) under sonication during 30 min using an
ultrasound bath. The amount of pranoprofen permeated and
retained through the cornea was determined by HPLC as described
previously for EE. The results are reported as the median ± SD and
median value (minimum – maximum range) of six and three rep-
licates for the amount of pranoprofen permeated and retained,
respectively.
2.9. Ocular permeation parameter
Lag time TL (h) values were calculated by plotting the
cumulative pranoprofen permeating the cornea versus time,
determining x-intercept by linear regression analysis. The corneal
permeability coefﬁcient KP (cm/h), partition coefﬁcient P1 (cm)
and diffusion coefﬁcient P2 (h1) were calculated from the
following equations:
KP ¼ P1  P2 ð7Þ
P1 ¼ J=ðA C0  P2Þ ð8Þ
P2 ¼ 1=ð6 TLÞ ð9Þ
where CO is the initial concentration of drug in the donor compart-
ment, A (0.64 cm2) is the exposed corneal surface. All the values are
reported as median value (minimum – maximum range) of three
replicates. Experimental data were processed using Graphpad prism
software (version 6 Demo) and compared by the application of a
non-parametric statistical Kruskal–Wallis Z test followed by the
Dunn’s multiple comparison tests. Values were considered to be
signiﬁcant at p < 0.05.
2.10. Corneal hydration levels
The corneal hydration level HL (%) of the cornea was deter-
mined at the end of the study of corneal permeation. The cornea
was carefully freed from the sclera ring, washed, weighed (Ww)
and dessicated at constant weight dried at 80 C and then
reweighed (Wd). The HL values are reported as median value (min-
imum – maximum range) of three replicates. HL was calculated
using the following expression:
HL ¼ ½1 ðWd=WwÞ  100 ð10ÞPlease cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejp2.11. In vitro ocular tolerance
The ocular tolerance of the HG_PF-NP formulations with a 0% or
1% azone was assessed by the HET-CAM test. This is an alternative
to animal testing (Draize test) described by Luepke [29]. To per-
form it, the shell and the inner membranes of 10-day-old chicken
eggs were previously removed, so that the CAM that separates
the embryo from the air chamber was visible, according to the
Invittox protocol [30], and the Journal ofﬁciel de la République
Française [31]. Tolerance was assessed by testing 6 eggs for each
sample, using 2 eggs treated with 0.1 N NaOH and 2 treated with
1% sodium lauryl sulfate solution as positive controls. After expos-
ing the CAM and rinsing it with PBS at pH 7.4, 300 lL of the test
solution was applied to the CAM. The intensity of the reaction
was semi-quantitatively assessed on a scale from 0 (no reaction)
to 3 (strong reaction). The time of the appearance and the intensity
of any reactions that occurred within 5 min were recorded. The
ocular irritation index (OII) was then calculated using the following
equation:
OII ¼ ð301 hÞ  5
300
þ ð301 lÞ  7
300
þ ð301 cÞ  9
300
ð11Þ
where h is the time (in seconds) until the start of a hemorrhage, l
until the start of lysis and c until the coagulation. The following
classiﬁcation was used: OII 6 0.9: slightly irritating; 0.9 6 OII 6 4.9:
moderately irritating; 4.9 6 OII 6 8.9: irritating; 8.9 6 OII 6 21:
severely irritating.
2.12. In vivo ocular tolerance
The irritancy of the HG_PF-NP formulations with a 0% or 1%
azone was evaluated in New Zealand white rabbits (2.5–3.0 kg) fol-
lowing the method described by Draize et al.[32,33] A single instil-
lation of 50 lL of each HG_PF-NP formulation was instilled in one
eye, using untreated contra-lateral eye as a control. Readings were
performed 1 h after sample application, then after 1, 2, 3, 4 and
7 days. The method provided an overall scoring system for grading
the severity of ocular lesions involving the cornea (opacity), iris
(inﬂammation degree) and conjunctiva (congestion, swelling and
discharge). The Draize score was determined by visual assessment
of change in these ocular structures. The mean total score (MTS)
was calculated as follows:
MTS ¼ X1ðnÞ
2
þ
XX2ðnÞ
2

XX3ðnÞ
5
ð12Þ
where x1 (n), x2 (n) and x3 (n) are the cornea, conjunctiva and iris
scores, respectively, being n the number of rabbits included in the
ocular tolerance assay.
2.13. In vivo anti-inﬂammatory efﬁcacy
The anti-inﬂammatory efﬁcacy of the HG_PF-NP formulations
was assessed using the method described by Spampinato Santi
et al. [34], the ocular inﬂammation was induced by ocular instilla-
tion of 50 lL SA (dissolved in PBS, 0.5% (w/v)) in the right eye of
eight groups of six rabbits (including control group). A volume of
50 lL of each HG_PF-NP formulation or 0.9% (w/v) isotonic saline
solution (control group) was instilled in the conjunctival sac of
the right eye 30 min before induction of ocular inﬂammation by
SA using left eye as an inﬂammation control. Inﬂammation was
quantiﬁed 30 min after AS instillation, then after 60, 90, 120, and
150 min, according to a modiﬁed Draize scoring system [32]. The
MTS was calculated as described previously in the ocular tolerance
assay (Eq. (12)). Since corneal transparency was not affected by the
instillation of SA, this parameter was not considered. The sum of
the conjunctival and iris score is expressed by the mean ± SD.f pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
b.2015.01.026
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3.1. Physicochemical characterization of the HG_PF-NPs
In previous studies, we have formulated pranoprofen in PLGA
nanoparticles as new delivery system suitable for the ocular route.
The Z-Ave of the optimized PF-F1NP and PF-F2NP formulations was
around 350 nm with PI values in the range of mono-disperse sys-
tems (PI < 0.1). Both formulations had net negative charge with
ZP values of – 7.41 mV and – 8.5 mV for PF-F1NPs and PF-F2NPs,
respectively. The percentage of encapsulated pranoprofen in the
polymeric matrix for these formulations reached 80% [20]. For
the present work, carbomer 934 was selected as hydrogel matrix
to incorporate the optimized PF-F1NP and PF-F2NP suspensions
in order to improve the biopharmaceutical proﬁle of pranoprofen
for the ocular application. The size and surface morphology of
the optimized PF-NPs after incorporation into HG were determined
by TEM. The mean diameters of HG_PF-NP formulations were
around 300 nm.
TEM image depicted in Fig. 1 reveals that the optimized NPs
after incorporation into HG were spherical shape and non-aggre-
gated. The results obtained show that the Z-Ave of the NPs incor-
porated into HG was similar to those of the NP suspensions.
The stability of the nanoparticles dispersed into the hydrogels
was assessed after 1 day of the production and after 90 days of
storage at 25 C. The results obtained by DL 1 day after the produc-
tion reveal two peaks, one at about 400 nm and another small peak
at 1 lm for all the HG_PF-NP formulations indicating an increase of
the Z-Ave and PI of the PF-NPs after incorporated into the hydro-
gels (see Fig. a, c, e and g in Supplementary materials). After
90 days of storage at 25 C, an increase in the Z-Ave values com-
pared with the results obtained 1 day after the production (see
Fig. b, d, f and h in Supplementary materials). The results given
in Table 2 show that the Z-Ave values obtained by PCS were similar
to those obtained by DL. This increase in the apparent particle size
was attributed to the strong entrapment of the particles within theFig. 1. Transmission electron microphotograph of the optimized NPs incorporated
into hydrogel.
Table 2
Mean particle size (Z-Ave) and zeta potential (ZP) of the HG_PF-NP formulations 1 day aft
Time HG_PF-F1NPs HG_PF-F2NPs
Day Z-Ave (nm) ZP (mV) Z-Ave (nm) ZP (mV)
1 385.20 ± 0.21 27.50 ± 0.10 391.30 ± 0.22 37.80 ± 0.13
90 495.70 ± 0.33 28.80 ± 0.11 471.50 ± 0.41 39.4 ± 0.12
Please cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejptridimensional gel structure, rather than real particle agglomer-
ates. These results are in accordance with those obtained by Gonz-
alez-Mira et al. [35]. These results are also in agreement with those
obtained by TEM (Fig. 1), since PF-NPs incorporated into HG
showed similar particle size in comparison with PF-NP suspension
and they were not aggregated. The particle size of formulations
intended for ocular instillation is of crucial importance and it
should not exceed 10 lm; larger sizes may cause a scratching feel-
ing of a foreign body in the eye and it would therefore compromise
patient’s comfort [36,37]. The results obtained by PCS in Table 2
also revealed a signiﬁcant increase of the ZP values of the PF-NPs
after incorporated into hydrogels. These results were attributed
to the adsorption of negatively charge of the jellifying agent mole-
cules onto the surface of the particles [38]. All the results obtained
from the stability study show that the HG_PF-NPs with or without
azone formulations exhibit appropriates physicochemical proper-
ties for ocular administration, which indicates that the gel network
of carbomer could not inﬂuence the morphology and size of the
NPs notably.496
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5163.2. Rheological measurements
The results obtained from the rheological characterization of
the HG_PF-NP formulations with or without azone are shown in
Table 3.
The rheological characterization of the HG_PF-NP formulations
with or without azone revealed a non-Newtonian behavior and
the pseudo-plastic character. The spreading properties and the
ability of controlling their viscosity showed for the HG_PF-NPs
are desirable for the ocular application. The results obtained in
Table 3 show that the HG_PF-NP formulations after 90 days of stor-
age at 25 C exhibited a decreased of the viscosity and Thixotropy
values regarding to the values observed at 8 days of the produc-
tion. Table 3 also reveals that the inclusion of azone in the
HG_PF-NP formulations leads a signiﬁcant viscosity increase in
the HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formulations.
These results are in accordance with the increase of the Z-Ave
and PI obtained after 90 days of storage at 25 C obtained by LD
(see Figure in Supplementary material) and PCS (Table 2) which
could be explained by the fact that the NPs characterized by a wide
polydispersity could pack better than those with a narrow polydis-
persity. The particles with a large polydispersity have more free
space to move around, which means that it was easier for the sam-
ple to ﬂow and a lower viscosity would be measured [39].
The oscillation frequency test was carried out from 0.01 to
10 Hz at a constant shear stress within the linear viscoelastic
region, in order to determine the related variation of storage mod-
ulus (G0) and loss modulus (G00) at 25 C, where the G0 describes the
elastic properties whereas G00 describes the viscous properties of
the sample.
With respect to the stress sweep test of the oscillatory study,
the critical stress was found at 10 Pa for the semi-solid formula-
tions assayed. These results suggest that none of the formulations
showed a weak structure. From the results of oscillatory stress
sweeps, a constant shear stress of 2 Pa (20% of the critical value)
was selected to perform the frequency sweep tests. The oscillatory
measurements applied to the formulations showed the prevalenceer production and after 90 days of storage at 25 C.
HG_PF-F1NPs-Azone HG_PF-F2NPs-Azone
Z-Ave (nm) ZP (mV) Z-Ave (nm) ZP (mV)
428.07 ± 0.13 34.20 ± 0.10 437.20 ± 0.10 31.87 ± 0.01
549.63 ± 0.10 37.77 ± 0.12 479.57 ± 0.12 37.63 ± 0.11
f pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
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Table 3
Rheological characterization of the HG_PF-NP formulations after 8 and 90 days of storage at 25 C.
Time HG_PF-F1NPs HG_PF-F2NPs HG_PF-F1NPs-Azone HG_PF-F2NPs-Azone
Days Viscosity (Pa s) Thixotropy (Pa/s) Viscosity (Pa s) Thixotropy (Pa/s) Viscosity (Pa s) Thixotropy (Pa/s) Viscosity (Pa s) Thixotropy (Pa/s)
8 1.64 ± 0.002 586.30 2.38 ± 0.001 1935.03 2.70 ± 0.002 3562.01 2.95 ± 0.002 3281.50
90 1.10 ± 0.001 542.45 0.93 ± 0.002 555.10 1.99 ± 0.001 3290.63 2.08 ± 0.002 3061.30
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NP formulations.557
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5933.3. In vitro drug release
An in vitro release study of pranoprofen from the HG_PF-NP for-
mulations, free drug solution (pranoprofen, dissolved in PBS) and
commercial eye drops (Oftalar

, pranoprofen 1.0 mg/mL) was per-
formed in Franz diffusion cell. As shown in Fig. 2, the release proﬁle
of pranoprofen from the free drug solution and the commercial eye
drops exhibited faster release than from the HG_PF-NP formula-
tions with or without azone. After 3 h, 100% of the drug was
released from the free drug solution or commercial eye drops.
Fig. 2 reveals that the HG_PF-NP formulations with or without
azone exhibit a sustained release behavior. The accumulative
amount of pranoprofen released from HG_PF-F1NPs, HG_PF-
F2NPs, HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone after 24 h
was 41.99%, 64.35%, 56.75% and 59.14%, respectively. Fig. 2 also
shows that the amount released of pranoprofen from HG_PF-
F1NPs and HG_PF-F1NPs-Azone was slightly smaller than HG_PF-
F2NPs and HG_PF-F2NPs-Azone, respectively. These results might
be attributed to the fact that during the preparation of the NPs
the viscosity increases when there is an increase in the cPVA from
5 mg/mL (PF-F2NPs) to 10 mg/mL (PF-F1NPs). This viscosity
increase could result in a more compact polymer matrix leading
to slower degradation of the polymer or slower diffusion of the
loaded pranoprofen from the nanoparticles [40].
In previous studies, we assessed the release proﬁle of pranopro-
fen from the PF-F1NP and PF-F2NP formulations. The results
obtained from this study revealed that both formulations showed
a sustained release behavior, with an initial burst attributed to
the pranoprofen adsorbed onto the nanoparticles’ surface, followed
by a slower release phase while the trapped pranoprofen slowly
diffuses out of the polymeric matrix into the release medium
[20]. However, the pranoprofen release rate was faster from the
pranoprofen-loaded nanoparticles than from the hydrogel formu-
lations with or without azone. All these results suggest that the dif-
fusion velocity of pranoprofen from the nanoparticles can be
modiﬁed due to higher viscosity of the hydrogels respect to the
nanoparticle suspensions. Nevertheless, the pranoprofen-loadedFig. 2. In vitro release proﬁles of PF from HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-
F1NPs-Azone, HG_PF-F2NPs-Azone, commercial eye drops and free drug solution.
Mean ± SD, n = 3. (For the interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Please cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpnanoparticles or hydrogels with or without azone could offer sus-
tained release of the drug in comparison with the free drug solu-
tion or commercial eye drops.
The amount of pranoprofen released from the HG_PF-F1NPs,
HG_PF-F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone, com-
mercial eye drops and free drug solution was adjusted to various
kinetic models, such as zero-order, ﬁrst-order, Higuchi, Hyperbola
and Korsmeyer–Peppas (Table 4). The AIC was determined for each
model. This parameter is an indicator of the model’s suitability for
a given dataset. The smaller the value of AIC, the better the model
adjusts the data.
From the AIC values (Table 4), it can be concluded that the
release curves of pranoprofen from HG_PF-F1NPs, HG_PF-F2NPs,
HG_PF-F2NPs-Azone, commercial eye drops and free drug solution
ﬁtted to the hyperbola model very well. The drug release mecha-
nism of the HG_PF-F1NPs-Azone formulation differed respect to
the other formulations, which adjusted to the ﬁrst order model.
These models had the smaller AIC value and, therefore, statistically,
described best the drug release mechanism. Taking into account
the diffusional exponent value (n) that is used to characterize dif-
ferent release mechanisms, n values 6 0.5 were obtained in all the
investigated HG_PF-NP formulations indicating that the release of
pranoprofen from the semi-solid formulations occurs by passive
diffusion. All these results suggest that the main factors that gov-
ern the release of the pranoprofen from the HG_PF-NP formula-
tions with or without azone are the amount of PVA present in
the formulation. Furthermore, the release rate is inﬂuenced by
the presence of pranoprofen in crystalline form, since the drug in
crystalline form should dissolve ﬁrst before being transported
out to the matrix by diffusion. As previously reported, in our study
that the intensity of some of the peaks of crystalline pranoprofen
present in the nanoparticles slightly increased when the concen-
tration of the drug increased from 1.0 mg/mL (PF-F2NPs) to
1.5 mg/mL (PF-F1NPs) by X-ray diffraction technique [20]. Addi-
tionally, the drug diffusion out of a hydrogel matrix dependent
on mechanical strength degradability, diffusivity, and other physi-
cal properties of hydrogel network [41].594
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6093.4. Corneal permeation study
Ex vivo corneal permeation study has been carried out up to 6 h,
to compare the permeation proﬁle of pranoprofen from the hydro-
gel formulations with or without azone, commercial eye drops and
free drug solution, and the results are shown in Fig. 3. The perme-
ation parameter values are summarized in Table 5.
At the end of the corneal permeation study, the cornea was used
to determine the amount of drug retained and the corneal hydra-
tion level. These results are exhibited in Table 6.
The corneal permeation parameters of pranoprofen calculated
from the amounts of permeated across cornea from the hydrogel
formulations with or without azone, commercial eye drops and
free drug solution in Table 5 were compared by the application
of a non-parametric statistical Kruskal–Wallis Z test followed by
the Dunn’s multiple comparison tests. From the statistical analysis
of the KP parameter obtained from these formulations, statistically
signiﬁcant differences (p < 0.05) were found between HG_PF-
F1NPs and HG_PF-F2NPs, HG_PF-F1NPs and commercial eye drops,f pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
b.2015.01.026
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Table 4
Mean parameter obtained after ﬁtting the release data of HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone, commercial eye drops and free drug solution to
different kinetic models.
Models Parameters HG_PF-F1NPs HG_PF-F2NPs HG_PF-F1NPs-Azone HG_PF-F2NPs-Azone Eye drops Free drug
Zero order AIC 75.35 80.67 86.52 88.03 110.78 109.76
First Order AIC 9.40 33.32 7.46 37.01 70.48 67.21
Higuchi AIC 55.12 52.86 69.11 71.01 101.97 102.63
Hyperbola 7.35 8.23 26.99 15.96 59.36 50.52
Korsmeyer- n 0.50 0.50 0.50 0.50 0.38 0.28
Peppas AIC 55.20 53.22 69.20 72.62 110.27 115.37
n, diffusional release exponent; AIC, Akaike information criterion.
Fig. 3. Ex vivo corneal permeation proﬁle of PF from the HG_PF-F1NPs, HG_PF-
F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone formulations, commercial eye
drops and free drug solution after 6 h. Mean ± SD, n = 6. (For the interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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16 February 2015HG_PF-F1NPs-Azone and HG_PF-F2NPs, HG_PF-F1NPs-Azone and
commercial eye drops. The HG_PF-F1NPs and HG_PF-F2NPs show
the lowest and highest KP value, respectively. Statistically signiﬁ-
cant differences (p < 0.05) were found between HG_PF-F1NPs and
HG_PF-F2NPs, HG_PF-F1NPs and commercial eye drops, HG_PF-
F1NPs and free drug, HG_PF-F2NPs-Azone and free drug, HG_PF-Table 5
Corneal permeation parameters of PF from HG_PF-NP formulations, commercial eye drops
Samples KP  102 (cm/h) P1  101 (cm)
HG_PF-F1NPs 1.50 (1.32–1.72)b,e 0.05 (0.04–0.0
HG_PF-F2NPs 5.56 (4.10–7.03)a,c 0.61 (0.53–0.6
HG_PF-F1NPs-Azone 2.68 (2.62–2.72)b,e 0.11 (0.08–0.1
HG_PF-F2NPs-Azone 3.26 (3.27–3.29) 0.20 (0.16–0.2
Eye drops 3.46 (3.42–3.62)a,c 0.89 (0.77–0.9
Free drug 3.32 (3.28–3.56) 1.00 (0.93–1.0
Results are reported as median value (minimum–maximum range) n = 6.
a Differences with HG_PF-F1NPs.
b Differences with HG_PF-F2NPs.
c Differences with HG_PF-F1NPs-Azone.
d Differences with HG_PF-F2NPs-Azone.
e Commercial eye drops.
f Free drug solution.
Table 6
Amounts of PF permeated (QP) and retained (QR) across cornea and corneal hydration leve
after 6 h.
Samples QP (%/cm2)
HG_PF-F1NPs 4.28 (3.6–4.93)
HG_PF-F2NPs 6.58 (5.35–7.08)
HG_PF-F1NPs-Azone 8.57 (7.20–9.59)
HG_PF-F2NPs-Azone 6.61 (8.51–8.17)
Eye drops 13.53 (11.12–13.57)
Free drug 13.62 (11.58–15.46)
Results are reported as median value and minimum – maximum range values (QP, n = 6
Please cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpF1NPs-Azone and commercial eye drops, HG_PF-F1NPs-Azone
and free drug for the P1 parameter. As shown in Table 5 the free
drug solution and HG_PF-F1NPs formulation exhibited the highest
and lowest P1 value, respectively. The statistical analysis of the P2
and TL parameters in Table 5 revealed a signiﬁcant difference
(p < 0.05) between HG_PF-F1NPs and commercial eye drops,
HG_PF-F1NPs and free drug, HG_PF-F2NPs-Azone and free drug,
HG_PF-F1NPs-Azone and commercial eye drops, HG_PF-F1NPs-
Azone and free drug. The HG_PF-F1NP formulation exhibits the
highest P2 value and the lowest P1 value, thus this formulation
shows the lowest KP value, since KP depends directly of P1 and P2.
The KP values obtained for the HG_PF-F2NP formulation, commer-
cial eye drops and free drug solution are directly related to the P1
parameter. Otherwise, the P2 values exhibited for the HG_PF-
F1NPs-Azone and HG_PF-F2NPs-Azone suggest that the diffusion
coefﬁcient of a drug is inﬂuenced by the presence of azone in the
formulation. The TL values obtained in Table 5 for the HG_PF-NPs
with or without azone are lower than those obtained for the com-
mercial eye drops and free drug solution. Therefore, these formula-
tions reach faster the steady state equilibrium than the commercial
eye drops and free drug solution.
The QP and QR values obtained for the commercial eye drops and
free drug solution are greater than those obtained for the hydrogeland free drug solution after 6 h.
P2  101 (h1) TL  101 (h)
5)b,e,f 32.64 (24.61–40.67)e,f 0.54 (0.41–0.68)e,f
9)a 8.98 (7.80–10.16) 1.90 (1.64–2.14)
4)e,f 25.87 (18.09–33.66)e,f 0.71 (0.50–0.92)e,f
4)f 16.93 (13.39–20.47)f 1.03 (0.81–1.25)f
1)a,c 3.98 (3.87–4.47)a,c 4.19 (3.73–4.31)a,c
7)a,d,c 3.30 (3.06–3.84)a,d,c 5.00 (4.34–5.45)a,d,c
l (HL) from the HG_PF-NP formulations, commercial eye drops and free drug solution
QR (%/cm2 g) HL (%)
18.23 (15.21–19.61) 79.87 (76.18–80.03)
16.32 (16.17–16.64) 77.56 (77.25–79.80)
24.56 (23.38–25.57) 76.98 (76.57–78.87)
20.71 (16.64–24.60) 78.19 (77.87–79.67)
52.55 (51.23–53.62) 77.44 (78.23–79.87)
50.41 (49.91–50.19) 78.12 (76.67–79.98)
; QR, n = 3; HL, n = 3).
f pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
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Fig. 4. Anti-inﬂammatory activity of PF from the HG_PF-F1NPs, HG_PF-F2NPs,
HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone formulations, commercial eye drops and
free drug solution. Mean ± SD. n = 6.
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free drug solution is inherently irritating to the eye and addition-
ally, pranoprofen is unstable in aqueous solution [42]. Otherwise,
the increased in the corneal permeation of pranoprofen showed
for the commercial eye drops can be explained due to this conven-
tional dosage form has a combination of benzalkonium chloride
(BAK) and edetate disodium (EDTA). The BAK produces an increase
of the amount of drug permeating the cornea by disruption of the
corneal epithelium. Additionally, it can also emulsify the corneal
epithelium, leading to increased partitioning of the drug [43].
Moreover, EDTA also increases the corneal permeability of differ-
ent drugs, by removing the extracellular calcium ions increasing
tight junction permeability [22,44,45].
Table 6 also shows that the QP and QR values of pranoprofen in
the cornea from the HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone
formulations are greater than those obtained from HG_PF-F1NPs
and HG_PF-F2NPs, respectively. The results suggest that the inclu-
sion of azone into HG formulation leads to the increase in the
amount of drug permeated and retained. Azone is one of the most
widely studied penetration enhancers of hydrophilic and lipophilic
drugs, which can be used as a safe and effective penetration enhan-
cer for human. Azone as a penetration enhancer is most effective at
low percentages; values ranging from 1% to 3% had been reported
in the literature. Although azone has been used for over 25 years,
several researchers continue to investigate its mechanism of
action. The mechanism of azone may be related with modiﬁcations
in the epithelial cell junctions and enhanced the inﬂux of water
and the transcorneal penetration of hydrophilic drugs but delayed
the apparent drug permeation of lipophilic drugs through the cor-
nea [22,23]. Regarding the corneal hydration analysis, the healthy
corneal has a hydration level of 76–80% [46]. According to the
results obtained in Table 6 for the HG_PF-NP formulations with
or without azone, commercial eye drops and free drug solution,
it can be concluded that during the assay the cornea was no
damage.
3.5. In vitro ocular tolerance
The studies using the HET-CAM are based on the direct applica-
tion of the sample onto the chorioallantoic membrane and the
observation of reactions, such as hemorrhage, intravasal coagula-
tion or lysis of blood vessels [47]. The results of the HET-CAM test
revealed optimal ocular tolerance of the HG_PF-NPs with or with-
out azone since no irritation reactions were detected within 5 min
of the assay (score 0).
3.6. In vivo ocular tolerance
Durand-Cavagna et al. evaluated in rabbits the ocular irritation
potential of 1% or 2% azone incorporated in ophthalmic vehicles,
such as poloxamer 188, hydroxyl-ethylcellulose, benzalkonium
chloride and phosphate buffer. Signs of ocular irritation were
detected. However, the reported results were inconclusive since
irritation could not be attributed to the presence of azone or ben-
zalkonium chloride [48]. In the present work, the irritancy of the
optimized HG_PF-NP formulations with or without azone was
evaluated in New Zealand white rabbits. The results of Draize test
showed good ocular tolerance of HG_PF-NPs with a 0% or 1% azone.
No signs of ocular irritancy were detected. These results are in
accordance with those obtained by HET-CAM test.
3.7. In vivo anti-inﬂammatory efﬁcacy
Fig. 4 shows the anti-inﬂammatory efﬁcacy effect of different
formulations containing pranoprofen in the ocular edema induced
by instillation of SA.Please cite this article in press as: G. Abrego et al., Biopharmaceutical proﬁle o
administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpAlthough the commercial eye drops and free drug solution show
the highest QR values of pranoprofen in the cornea, the anti-inﬂam-
matory efﬁcacy values obtained for the commercial eye drops are
lower compared to the other tested formulations (Fig. 4). Until
120 min, the free drug solution exhibits slower anti-inﬂammatory
activity than the HG_PF-NP formulation with or with azone. The
results obtained for the commercial eye drops and free drug solu-
tion could be explained by the fact that these formulations show TL
values greater than those obtained for the HG_PF-NPs with or
without azone. Thus, the commercial eye drops and free drug solu-
tion reach slower steady state equilibrium than the HG_PF-NPs,
therefore show slower anti-inﬂammatory activity than the other
tested formulation. Fig. 4 also shows that the HG_PF-F1NPs-Azone
and HG_PF-F2NPs-Azone formulations signiﬁcantly reduced the
ocular edema, compared to the HG_PF-F1NP and HG_PF-F2NP for-
mulations, respectively. According to the results obtained in this
study, the inclusion of azone into the HG_PF-NP formulations leads
to the increase of the anti-inﬂammatory efﬁcacy of pranoprofen in
the cornea. The anti-inﬂammatory efﬁcacy values exhibited for the
HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formulations are
correlated directly with the amount of drug retained in the cornea.
Therefore, the ocular application of the HG_PF-F1NPs-Azone or
HG_PF-F2NPs-Azone formulations could more effective in the
treatment of ocular edema that the HG_PF-F1NP or HG_PF-F2NP
formulations.
4. Conclusions
The optimized PF-F1NP and PF-F2NP suspensions were success-
fully dispersed into blank hydrogels or hydrogels containing 1%
azone. The hydrogel formulations showed a rheological behavior
and physicochemical properties suitable for ocular pranoprofen
delivery. The HG_PF-NPs with or without azone exhibited sus-
tained release behavior with a slower release of pranoprofen.
According to the results obtained from the corneal permeationf pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular
b.2015.01.026
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16 February 2015and anti-inﬂammatory efﬁcacy studies, the commercial eye drops
and free drug solution showed the highest QR values of pranopro-
fen in the cornea. However, both formulations cannot be consid-
ered optimal in the treatment of ocular diseases due to the free
drug solution is inherently irritating to the eye and additionally,
pranoprofen is unstable in aqueous solution. Besides, following
the instillation of commercial eye drops, the most of the drugs is
removed, by ear dilution and tear turn over from the surface of
the eye due to the low viscosity of these conventional dosage
forms. The HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formula-
tions signiﬁcantly reduced the ocular edema, compared with other
tested formulations. These results indicate that the inclusion of
azone into the HG_PF-NP formulations leads to the increase of
the anti-inﬂammatory efﬁcacy effect of pranoprofen in the cornea.
Therefore, the ocular application of these formulations could be
more effective in the treatment of ocular edema.
The HG_PF-NPs with 0% or 1% azone showed an optimal ocular
tolerance by the in vitro e in vivo ocular irritation test. All these
results suggest that the ocular administration of the HG_PF-
F1NPs-Azone or HG_PF-F2NPs-Azone formulations could be an
effective and appropriate system for ophthalmic administration
of pranoprofen, improving the biopharmaceutical proﬁle of this
drug, thus enhancing the local anti-inﬂammatory and analgesic
effect of this drug and, consequently, improving the patient’s com-
pliance. However, the formulations for ocular applications based
on carbomer hydrogels must be preserved in order to avoid the
growth of microorganisms, but unfortunately the action of the
ophthalmic preservatives is non-speciﬁc and these can cause toxic-
ity or damage to the ocular structure. In order to ensure the conser-
vation of the HG_PF-NP formulation, additional studies related to
sterilization by autoclave or gamma irradiation would be required.833
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